Tag: chemistry analyzer

Lab Scheme Recruits Hospitals To Bill as In-Network Providers

CEO SUMMARY: Management companies using a new generation of potentially fraudulent schemes are targeting hospitals and health systems for arrangements that use questionable means to increase lab test volume and revenue. The management companies often use the term “hospital outpatient department (HOPD) billing model” to describe these arrangements. The scammers want the hospitals, as in-network

View Article

Root Cause Analysis Used To Find Source of Errors

CEO SUMMARY: It is a reminder that today’s sophisticated laboratory test systems still have the potential to malfunction in unexpected ways. This spring, following installation and validation of a new chemistry instrument, one Canadian hospital laboratory quickly recognized that a series of random errors were a sign that the instrument had issues—but not before specimens

View Article

Office-Based Physicians Want In-Clinic Laboratories

CEO SUMMARY: Interest by office-based physicians in creating an in-clinic medical testing laboratory is on the increase. This has direct consequences for independent commercial labs, hospital lab outreach programs, and anatomic pathology groups, since office- based physicians are a primary source of lab test referrals. One consultant says that 60% to 70% of the volume

View Article

Global Laboratory Trends Dominated by Rising Costs and Labor Shortage

“The Web has transformed many industries and it’s clearly affected our industry. This trend will help raise the bar in quality and overall performance among laboratories and manufacturers.”
—Jim Reid-Anderson
Chairman, President, and CEO of Dade Behring
CEO Summary: Recently, THE DARK REPORT conducted a roundtable interview with executives of Dade Behring. Present were Jim Reid-Anderson, Chairman, President

View Article

December 18, 2006 “Intelligence: Late Breaking Lab News”

Last Friday, Luminex Corporation of Austin, Texas announced that it would acquire Tm Bioscience Corp. of Toronto, Ontario. Luminex will pay $44 million, which represents a 41.5% premium for Tm shares based on the December 14 closing price. Tm Bioscience has tests for DNA-based diagnostics, including tests for infectious diseases and genetic mutations related to

View Article

Tour of Korean Labs Has Plenty to Teach

CEO SUMMARY: Faster turnaround times and better quality seem to be some common motivations for installing automation in the three Korean labs visited by THE DARK REPORT last month. All the laboratories were extra clean and neat, relative to most North American labs. Each of the laboratories visited reports a high degree of satisfaction with the performance of

View Article